Paper Details

  1. Home
  2. Paper Details

A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.

Author: CawleyJ C, DaviesJ M, NewlandA C, PearceR, PhillipsJ K, ReillyJ T, Sherlaw-JohnsonC

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study of 67 patients with relapsed or resistant multiple myeloma found that VAD and MOD had similar efficacy in achieving plateaux. VAD was associated with a longer median duration of plateaux, but also with more severe toxicity, including hair loss, thrombocytopenia, hematuria, and cutaneous toxicity.
Paper Details　
Original Abstract of the Article :
67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone). 12/30 (40%) patients receiving VAD and 15/37 (41%) patients receiving MOD achieved plateaux. The median duration ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/10428199509056859

データ提供：米国国立医学図書館（NLM）

A Race Against Time: Treating Relapsed and Resistant Multiple Myeloma

The fight against multiple myeloma, a complex and challenging cancer, is a long and arduous journey. This study, like a caravan traversing a vast desert, explores the effectiveness of two chemotherapy regimens, VAD and MOD, in treating relapsed and resistant multiple myeloma. The researchers, armed with their scientific tools and a spirit of discovery, sought to compare the efficacy and toxicity of these treatment approaches. Their findings offer valuable insights into the complexities of myeloma treatment, guiding clinicians in their decision-making process.

A Shifting Landscape: Comparing Treatment Regimens

The results of this study reveal that both VAD and MOD chemotherapy regimens demonstrate comparable efficacy in treating relapsed and resistant multiple myeloma, but MOD appears to be less toxic. This finding is significant, as it provides clinicians with a valuable tool for selecting the optimal treatment approach based on individual patient needs and risk profiles. The researchers observed a longer median duration of plateaux (periods of disease stability) in patients receiving VAD compared to those receiving MOD, highlighting the potential for a more enduring therapeutic effect.

Dr. Camel's Conclusion

This study provides valuable insights into the treatment of relapsed and resistant multiple myeloma, demonstrating the comparable efficacy of VAD and MOD chemotherapy regimens, with MOD presenting a more favorable toxicity profile. These findings offer clinicians a crucial tool for navigating the complex landscape of myeloma treatment, ultimately improving patient care.

Date :
  1. Date Completed 1995-11-08
  2. Date Revised 2019-01-16
Further Info :

Pubmed ID

7549839

DOI: Digital Object Identifier

10.3109/10428199509056859

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.